chills/kansè

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 938 rezilta yo

Rigor and Reproducibility: A Systematic Review of Salivary Cortisol Sampling and Reporting Parameters Used in Cancer Survivorship Research.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Salivary cortisol is a commonly used biomarker in cancer survivorship research; however, variations in sampling protocols and parameter reporting limit comparisons across studies. Standardized practices to provide rigor and reproducibility of diurnal salivary cortisol sampling and reporting are not

Mathematical rigor is necessary, but for men with prostate cancer, clinical relevance is the priority.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Subanesthetic ketamine for cancer pain and scientific rigor in cancer pain trials. A reply to Jackson et al.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Out of the Darkness, Into Light: The Scientific Rigor of Lung Cancer Clinical Trials in the Age of Enlightenment

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Helpful hints in caring for patients receiving biotherapy. Rigors associated with outpatient tumor necrosis factor administration.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Diffuse F-18 FDG uptake in skeletal muscles secondary to chills resulting from sepsis: a cause for underestimation of viable tumor.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Chills and fever as the first presentation of hepatic perivascular epithelioid cell tumor.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Prostate cancer presenting with fever and rigors.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Prostate cancer presenting with fever and rigors.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Endotoxin and cancer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Exposure to endotoxin, a component of gram-negative bacterial cell walls, is widespread in many industrial settings and in the ambient environment. Heavy-exposure environments include livestock farms, cotton textile facilities, and saw mills. Concentrations are highly variable in

Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND NGR-hTNF consists of human tumour necrosis factor-alpha (hTNF-alpha) fused to the tumour-homing peptide NGR, a ligand of an aminopeptidase N/CD13 isoform, which is overexpressed on endothelial cells of newly formed tumour blood vessels. NGR-TNF showed a biphasic dose-response curve in

Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND asparagine-glycine-arginine-human tumour necrosis factor (NGR-hTNF), an agent selectively damaging the tumour vasculature, showed a biphasic dose-response curve in preclinical models. Previous phase I trials of NGR-hTNF indicated 0.8 and 45 μg/m(2) as optimal biological and

Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Twenty-six patients with advanced cancer refractory to standard therapy were treated with recombinant human tumor necrosis factor (rTNF) in a study aimed at determining the toxicity and tolerance of rTNF and at seeking evidence of antitumor activity. The study design involved two treatments per week

Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To report the preliminary results of a Phase I/II study combining radiotherapy and in situ gene therapy (adenovirus/herpes simplex virus thymidine kinase gene/valacyclovir) with or without hormonal therapy in the treatment of prostate cancer. METHODS Arm A: low-risk patients (T1-T2a,

Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE The aim of this study was to investigate the efficacy and safety of intraperitoneal catumaxomab in heavily pretreated patients with chemotherapy-refractory ovarian cancer and recurrent symptomatic malignant ascites. METHODS The study is a single-arm open-label multicenter US phase II

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye